Who is sponsoring NCT00574379?

NCT00574379 is sponsored by Faes Farma, S.A..

What condition does NCT00574379 study?

NCT00574379 studies Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity.

What drugs are being tested in NCT00574379?

Interventions: Bilastine, Placebo.

What is the status of NCT00574379?

NCT00574379 is currently COMPLETED.

Last reviewed 2019-02-13 · How we verify

A Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in The Treatment of the Symptoms of Seasonal Allergic Rhino-Conjunctivitis With Allergy to Mountain Cedar Pollen

NCT00574379 Phase 2 COMPLETED

Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and Oklahoma based on the mean change from baseline in Reflective Total Nasal Symptom Scores (TNSS) assessed over 14 days of treatment.

Details

Lead sponsor	Faes Farma, S.A.
Phase	Phase 2
Status	COMPLETED
Enrolment	805
Start date	2007-12
Completion	2008-03

Conditions

Seasonal Allergic Rhinitis
Hay Fever
Allergic Conjunctivitis
Hypersensitivity

Interventions

Bilastine
Placebo

Primary outcomes

Change in nasal symptom scores — 14 days

Countries

United States